Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Heart failure in the last year: progress and perspective
Daniela Tomasoni, Marianna Adamo, Markus S. Anker, et al.
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3505-3530
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 431-441
Open Access | Times Cited: 108
Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies
Guangchen Li, Yifu Cheng, Chi Han, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 11, pp. 1300-1321
Open Access | Times Cited: 59
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care
Daniela Tomasoni, Julie K.K. Vishram‐Nielsen, Matteo Pagnesi, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 3, pp. 1507-1523
Open Access | Times Cited: 52
Heart failure: an update from the last years and a look at the near future
Mauro Riccardi, Antonio Maria Sammartino, Massimo Piepoli, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 6, pp. 3667-3693
Open Access | Times Cited: 49
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Jay Patel, Negin Rassekh, Gregg C. Fonarow, et al.
Drugs (2023) Vol. 83, Iss. 9, pp. 747-759
Closed Access | Times Cited: 25
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Domingo A. Pascual‐Figal, Antoni Bayés‐Genís, Paola Beltrán-Troncoso, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 53
Chapter 1: The Burden of Heart Failure
Richard E. Pratley, Xuan Guan, Richard J. Moro, et al.
The American Journal of Medicine (2024) Vol. 137, Iss. 2, pp. S3-S8
Open Access | Times Cited: 8
A year in heart failure: an update of recent findings
Lorenzo Stretti, Dauphine Zippo, Andrew J.S. Coats, et al.
ESC Heart Failure (2021) Vol. 8, Iss. 6, pp. 4370-4393
Open Access | Times Cited: 39
Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
Xiaohui Lin, Hsin-Tang Lin, Maobai Liu, et al.
Journal of Thoracic Disease (2022) Vol. 14, Iss. 5, pp. 1588-1597
Open Access | Times Cited: 20
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure
Haiping Du, Li Xiao, Weifang Zhao, et al.
Journal of Healthcare Engineering (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 16
Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations
Andrii Maryniak, Nodari Maisuradze, Rafsan Ahmed, et al.
Cardiology Journal (2022) Vol. 29, Iss. 4, pp. 670-679
Open Access | Times Cited: 15
Budget impact analyses for treatment of heart failure. A systematic review
Abedin Teimourizad, Abdosaleh Jafari, Firooz Esmaeilzadeh
Heart Failure Reviews (2024) Vol. 29, Iss. 4, pp. 785-797
Closed Access | Times Cited: 3
JCS 2023 Guideline on Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease
Takatoshi Kasai, Takashi Kohno, Wataru Shimizu, et al.
Circulation Journal (2024) Vol. 88, Iss. 11, pp. 1865-1935
Open Access | Times Cited: 3
Diuretic-induced hypokalaemia: an updated review
Ziying Lin, Louisa Y.F. Wong, Bernard M.Y. Cheung
Postgraduate Medical Journal (2021) Vol. 98, Iss. 1160, pp. 477-482
Closed Access | Times Cited: 19
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction
Mauro Riccardi, Daniela Tomasoni, Enrico Vizzardi, et al.
Heart Failure Reviews (2022)
Open Access | Times Cited: 13
Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
Federico Ferro, Renza Spelat, Camilla Valente, et al.
Biomolecules (2022) Vol. 12, Iss. 7, pp. 969-969
Open Access | Times Cited: 12
Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
Lu Wang, Xuechen Huo, Haiyan Sun, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Effects of sacubitril-valsartan on aging-related cardiac dysfunction
Marialucia Telesca, Antonella De Angelis, Maria Donniacuo, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176794-176794
Open Access | Times Cited: 2
Highlighting the South Asian Heart Failure Epidemic
Nikhilesh Srinivasan, Nageshwara Gullapalli, Kevin Shah
Cardiac failure review (2024) Vol. 10
Open Access | Times Cited: 2
Transcatheter edge‐to‐edge mitral valve repair for post‐myocardial infarction papillary muscle rupture and acute heart failure: A systematic review
Filippo Calì, Matteo Pagnesi, Elisa Pezzola, et al.
Catheterization and Cardiovascular Interventions (2023) Vol. 102, Iss. 1, pp. 138-144
Closed Access | Times Cited: 6
ALKBH5 inhibitors as a potential treatment strategy in heart failure—inferences from gene expression profiling
Sumra Komal, Atia Gohar, Saad Althobaiti, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
Spyros Kolovos, L Bellanca, Harinala Groyer, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 6, pp. 3385-3397
Open Access | Times Cited: 6
Taking It Personally: 3D Bioprinting a Patient-Specific Cardiac Patch for the Treatment of Heart Failure
Niina Matthews, B Pandolfo, Daniel Moses, et al.
Bioengineering (2022) Vol. 9, Iss. 3, pp. 93-93
Open Access | Times Cited: 10
A novel nutritional index as a predictor of mortality in dilated cardiomyopathy: a retrospective study
Can Wang, Yali Qing, Wu‐Xian Chen, et al.
PeerJ (2022) Vol. 10, pp. e12704-e12704
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top